BiotechTube

Acetylcysteine + Paracetamol + Phenylephrine

Phase 3Withdrawn
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Common Cold

Conditions

Common Cold

Trial Timeline

Sep 20, 2024 → Apr 30, 2025

NCT ID
NCT05070650

About Acetylcysteine + Paracetamol + Phenylephrine

Acetylcysteine + Paracetamol + Phenylephrine is a phase 3 stage product being developed by Sandoz Group for Common Cold. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05070650. Target conditions include Common Cold.

What happened to similar drugs?

5 of 16 similar drugs in Common Cold were approved

Approved (5) Terminated (2) Active (10)
✅Pseudoephedrine/ParacetamolJohnson & JohnsonApproved
✅Dextromethorphan + PlaceboNovartisApproved
✅VivaglobinCSLApproved
✅Acetylsalicylic acid (Aspirin, BAYE4465) + Paracetamol + PlaceboBayerApproved
✅Aspirin (Acetylsalicylic acid, BAYE4465) + PlaceboBayerApproved
🔄Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mgNovartisPhase 3
🔄XylometazolineNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05070650Phase 3Withdrawn

Competing Products

20 competing products in Common Cold

See all competitors
ProductCompanyStageHype Score
Nasal Glucagon + OxymetazolineEli LillyPhase 1
29
New Formulation Phenylephrine HCl + Marketed Phenylephrine HCl + PlaceboJohnson & JohnsonPhase 2
27
Pseudoephedrine/ParacetamolJohnson & JohnsonApproved
43
Zostavax®MerckPre-clinical
18
Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mgNovartisPhase 3
40
CDZ173NovartisPhase 2/3
38
Dextromethorphan + PlaceboNovartisApproved
35
XylometazolineNovartisPhase 3
40
N-acetylcysteine + PlaceboNovartisPhase 2
35
Advil Congestion Relief + Advil Allergy and Congestion Relief + ParacetamolPfizerPhase 3
32
pseudoephedrine hydrochloride 30 mg tablets + Placebo tabletsPfizerPhase 3
40
gammaglobulinCSLPre-clinical
26
Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)CSLPhase 3
40
VivaglobinCSLApproved
43
Acetylsalicylic acid (Aspirin, BAYE4465) + Paracetamol + PlaceboBayerApproved
40
Aspirin (Acetylsalicylic acid, BAYE4465) + PlaceboBayerApproved
40
Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain + Acetylsalicylic Acid (Aspirin, BAYE4465) + Lidocain + PlaceboBayerPhase 3
37
Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine + Acetylsalicylic Acid (Aspirin, BAYE4465) + Pseudoephedrine + PlaceboBayerPhase 3
37
Acetylsalicylic Acid (Aspirin, BAYE4465) + Pseudoephedrine + PlaceboBayerPhase 3
37
A-101Aclaris TherapeuticsPhase 3
30